No Data
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (Rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Earnings Preview: BHC to Report Financial Results Post-market on October 30
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Raises Target Price to $10
Express News | Bausch Health Companies Inc : RBC Raises Target Price to $10 From $8.5
Bausch Health Price Target Raised to $10 From $8.50 at RBC Capital
Bausch Health (BHC) Reports Next Week: What to Expect